Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
3.8
Journals
Bioengineering
Special Issues
Advanced Research in Osteoarthritis and Osteoarthrosis Management and Regenerative Strategies
share announcement

Advanced Research in Osteoarthritis and Osteoarthrosis Management and Regenerative Strategies

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Cellular and Molecular Bioengineering".

Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 5743

Special Issue Editors

Dr. Antonio Graziano

E-Mail Website
Guest Editor
Sbarro Health Research Organization (SHRO), Temple University, 1900 N 12th St., Philadelphia, PA 19122, USA
Interests: regenerative medicine; micrografting; biotechnology; biology; tissue engineering; cartilage; bioprocess
Dr. Marco Marcarelli

E-Mail Website
Guest Editor
Mauriziano Hospital, 10126 Turin, Italy
Interests: orthopedics; foot surgery; Achilles tendon

Special Issue Information

Dear Colleagues,

Osteoarthritis (OA) is a degenerative disease that leads to the loss of cartilage. Although it is commonly referred to as a disease of the joint cartilage, it affects all joint tissues equally and its pathogenesis is not yet completely understood. On the other hand, osteoarthrosis is a disorder of synovial joints that results from the destruction of the cartilage and subchondral bone. Both of these pathological conditions lead to chronic pain and disability in affected patients, and as a result, they represent a considerable socioeconomic burden. Despite the currently available therapies and advances in research, unfulfilled medical needs persist for OA treatment.

This Special Issue, entitled “Recent Advances in Osteoarthritis and Osteoarthrosis Management and Regenerative Strategies”, will focus on original research papers, case reports and comprehensive reviews that address cutting-edge experimental methodologies for multiscale investigations about tissue engineering and regenerative approaches by bringing together contributions from worldwide experts on stem cell biology, tissue engineering-based approaches, cartilage surgery strategies, cellular and experimental therapies and bioprocess development. The topics of interest for this Special Issue include, but are not limited to, the following:

  1. Advanced experimental techniques for characterizing inflammatory pathways;
  2. Novel biomaterials for bone/cartilage regeneration/reconstruction;
  3. Growth, remodeling and repair in bone/cartilage tissues;
  4. Investigations about new regenerative approach not only stem cells-based;
  5. Molecular and cellular mechanisms involved in the cartilage destruction;
  6. Current and future directions for 3D bioprinting to develop osteochondral unit constructs.

Dr. Antonio Graziano
Dr. Marco Marcarelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • osteoarthritis
  • osteoarthrosis
  • tissue engineering
  • tissue regeneration
  • grafting
  • biomaterials
  • cartilage repair
  • inflammation
  • cytokines
  • joints degeneration

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 3205 KiB  
Article
The Differential Expressions and Associations of Intracellular and Extracellular GRP78/Bip with Disease Activity and Progression in Rheumatoid Arthritis
by Guoyin Liu, Jianping Wu, Yongqiang Wang, Yuansheng Xu, Chun Xu, Guilin Fang, Xin Li and Jianmin Chen
Bioengineering 2025, 12(1), 58; https://doi.org/10.3390/bioengineering12010058 - 13 Jan 2025
Viewed by 994
Abstract
GRP78/BiP, a stress-induced protein and autoantigen in rheumatoid arthritis (RA), exhibits different expressions in various biological fluids and tissues, including blood, synovial fluid (SF), and synovium, all of which are pertinent to the disease activity and progression of RA; however, there is a [...] Read more.
GRP78/BiP, a stress-induced protein and autoantigen in rheumatoid arthritis (RA), exhibits different expressions in various biological fluids and tissues, including blood, synovial fluid (SF), and synovium, all of which are pertinent to the disease activity and progression of RA; however, there is a scarcity of data linking both intracellular and extracellular GRP78/Bip to disease activity and progression of RA. This study was undertaken to investigate the differential expression of GRP78/Bip in blood, SF, and synovium, and to determine their association with disease activity and progression of RA. Patients with RA, osteoarthritis (OA), and traumatic meniscal injury (TMI) without radiographic OA were consecutively recruited for the study. Among patients with RA, six different subgroups were established based on their disease activity and progression. Disease activity was measured using the DAS28 (Disease activity scores in 28 joints) criterion, while disease progression was evaluated using the Steinbrocker classification grade. The levels of GRP78/Bip, TNF-α, and IL-10 were significantly elevated in the serum, SF, and synovium of patients with RA when compared to both the control (CON, TMI Patients) and the inflammation control (iCON, OA Patients) groups (p < 0.05). In terms of disease activity status, as opposed to remission status in RA, the levels of GRP78/Bip, TNF-α, and IL-10 were all elevated in serum and synovium (p < 0.05). However, GRP78/Bip and IL-10 levels were found to be reduced in SF, while TNF-α levels remained elevated. With respect to disease progression in RA, GRP78/Bip levels exhibited a positive correlation with both the stage of RA and the levels of TNF-α and IL-10 in serum and synovium. Nonetheless, a negative correlation was observed between GRP78/Bip levels and the stage of RA in SF, while positive correlations with the levels of TNF-α and IL-10 persisted. The differential expression of GRP78/Bip in blood, SF, and synovium indicated that the potential role and function of GRP78/Bip might vary depending on its specific location within these biological fluids and tissues. The presence of intracellular and extracellular GRP78/Bip was associated with disease activity and progression of RA, suggesting the involvement of GRP78/Bip in the pathogenesis and development of this debilitating autoimmune disorder, as well as its potential as a biomarker for monitoring disease activity and progression of RA. Full article
(This article belongs to the Special Issue Advanced Research in Osteoarthritis and Osteoarthrosis Management and Regenerative Strategies)
►▼ Show Figures

Figure 1

8 pages, 1362 KiB  
Article
Efficacy of Autologous Micrografting Technology in Managing Osteoarthritis Pain: A Pilot Study
by Camilo Partezani Helito, Valeria Pessei, Cecilia Zaniboni and Ilie Muntean
Bioengineering 2024, 11(11), 1119; https://doi.org/10.3390/bioengineering11111119 - 6 Nov 2024
Viewed by 983
Abstract
Osteoarthritis (OA) is one of the most common joint diseases worldwide, predominantly present in elderly people. Being a major source of pain for patients, it is debilitating and leads inevitably to a reduction in quality of life. The management of OA needs a [...] Read more.
Osteoarthritis (OA) is one of the most common joint diseases worldwide, predominantly present in elderly people. Being a major source of pain for patients, it is debilitating and leads inevitably to a reduction in quality of life. The management of OA needs a personalized and multidimensional approach, resulting in the emergence of new regenerative and non-invasive methods, such as the use of micrografts. In this pilot study, Rigenera® Technology was employed to obtain micrografts of cartilage tissue to be injected into the knees of 10 patients with osteoarthritic pain. To assess the efficacy of the treatment concerning pain reduction at this site, patients were asked to complete KOOS and WOMAC questionnaire and a VAS test before and after the procedure. The results presented in this article show how Rigenera® treatment can potentially improve OA symptoms, alleviating pain in patients. Full article
(This article belongs to the Special Issue Advanced Research in Osteoarthritis and Osteoarthrosis Management and Regenerative Strategies)
►▼ Show Figures

Graphical abstract

12 pages, 3907 KiB  
Article
Prospective Observational Study of a Non-Arthroscopic Autologous Cartilage Micrografting Technology for Knee Osteoarthritis
by Dimitrios Tsoukas, Ilie Muntean, Christos Simos and Ruben Sabido-Vera
Bioengineering 2023, 10(11), 1294; https://doi.org/10.3390/bioengineering10111294 - 8 Nov 2023
Cited by 2 | Viewed by 2305
Abstract
Autologous micrografting technology (AMT®) involves the use of autologous micrografts to stimulate/enhance the repair of damaged tissue. This study assessed the efficacy and safety of the AMT® procedure in patients with early stages of knee osteoarthritis. Briefly, the AMT® [...] Read more.
Autologous micrografting technology (AMT®) involves the use of autologous micrografts to stimulate/enhance the repair of damaged tissue. This study assessed the efficacy and safety of the AMT® procedure in patients with early stages of knee osteoarthritis. Briefly, the AMT® procedure involved extraction of auricular cartilage, disaggregation using the Rigeneracons® SRT in 4.0 mL of saline solution, and injection of the disaggregated micrografts into the external femorotibial compartment area of the affected knee. Ten patients (4 men, 6 women; age range: 37–84 years) were included in the study. In all patients, there was a steady improvement in knee instability, pain, swelling, mechanical locking, stair climbing, and squatting at 1- and 6-months post-procedure. Improvement in mobility was observed as early as 3 weeks post-procedure in 2 patients. Significant improvements were seen in mean scores of all five subscales of Knee Injury and Osteoarthritis Outcome Score (KOOS [KOOS symptoms, KOOS pain, KOOS ADL, KOOS sport and recreation, and KOOS quality-of-life]) between pre-procedure and 1- and 6-months post-procedure (all p ≤ 0.05). Autologous auricular cartilage micrografts obtained by AMT® procedure (using Rigenera® technology) is an effective and safe protocol in the treatment of early stage knee osteoarthritis. These encouraging findings need to be validated in a larger patient population and in a randomized clinical trial (RCT). Full article
(This article belongs to the Special Issue Advanced Research in Osteoarthritis and Osteoarthrosis Management and Regenerative Strategies)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop